Peripheral blood stem cell transfusion for marrow replacement.
A patient is presented who was treated with ablative therapy for Hodgkin's disease and rescued by reinfusion of peripheral blood stem cells (PBSC). The PBSC were used because previous therapy (chemotherapy and radiation to the pelvis) had resulted in fatty hypocellular marrow which was inadequate for marrow transplantation. The PBSC were collected by leukapheresis before and after recovery of the marrow from suppression with cyclophosphamide to bring the stem cells into cohort cycle and to increase the proportion of stem cells in the peripheral blood for collection. The patient showed a successful recovery on a time scale somewhat longer cells administered, the absence of stimulation by granulocyte macrophage-colony stimulating factor or other cytokine, or potential damage done to stromal elements during previous radiation and chemotherapy. The patient remains in clinical complete remission, fully engrafted, more than one year since his autologous transplant.
Morse
E E
EE
Department of Laboratory Medicine, University of Connecticut Health Center, Farmington 06030.
Dainiak
N
N
Sorba
S
S
King
C
C
Gaffney
J
J
Ascensao
J L
JL
D015703:Antigens, CD / Q000032:analysis; D018952:Antigens, CD34; D000970:Antineoplastic Agents / Q000009:adverse effects; D001853:Bone Marrow / Q000473:pathology; D001855:Bone Marrow Diseases / Q000209:etiology / Q000601:surgery*; D006410:Hematopoiesis; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000276:immunology; D006689:Hodgkin Disease / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011878:Radiotherapy / Q000009:adverse effects; D014182:Transplantation, Autologous
D015703:Antigens, CD; D018952:Antigens, CD34; D000970:Antineoplastic Agents